Recent Finacing
Recent Raise
Spruce Biosciences is a clinical-stage biopharma developing tildacerfont, an oral non-steroidal CRF1 receptor antagonist for congenital adrenal hyperplasia, advancing late-stage adult trials, pediatric proof-of-concept, and related ACTH-driven indications.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
